Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCH NASDAQ:NDRA NASDAQ:NXGL NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$0.85-6.6%$1.15$0.74▼$3.09$21.67M2.098.56 million shs1.20 million shsNDRAENDRA Life Sciences$7.00-5.5%$5.03$2.90▼$22.68$5.58M-0.09749,247 shs54,167 shsNXGLNexGel$2.36-6.7%$2.44$2.10▼$5.10$20.41M0.5742,129 shs100,831 shsXAIRBeyond Air$2.47-4.3%$2.43$2.02▼$13.52$20.47M0.29248,062 shs174,690 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical-6.59%-10.44%-36.57%-47.20%-68.75%NDRAENDRA Life Sciences-5.53%+2.79%+46.44%-1.69%-4.76%NXGLNexGel-6.72%-11.61%-3.67%-2.48%-19.73%XAIRBeyond Air-4.26%-8.18%+2.07%-24.23%-62.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCHEnvoy Medical$0.85-6.6%$1.15$0.74▼$3.09$21.67M2.098.56 million shs1.20 million shsNDRAENDRA Life Sciences$7.00-5.5%$5.03$2.90▼$22.68$5.58M-0.09749,247 shs54,167 shsNXGLNexGel$2.36-6.7%$2.44$2.10▼$5.10$20.41M0.5742,129 shs100,831 shsXAIRBeyond Air$2.47-4.3%$2.43$2.02▼$13.52$20.47M0.29248,062 shs174,690 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCHEnvoy Medical-6.59%-10.44%-36.57%-47.20%-68.75%NDRAENDRA Life Sciences-5.53%+2.79%+46.44%-1.69%-4.76%NXGLNexGel-6.72%-11.61%-3.67%-2.48%-19.73%XAIRBeyond Air-4.26%-8.18%+2.07%-24.23%-62.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCHEnvoy Medical 2.00Hold$9.501,017.65% UpsideNDRAENDRA Life Sciences 2.00Hold$50.00614.29% UpsideNXGLNexGel 1.00SellN/AN/AXAIRBeyond Air 2.67Moderate Buy$11.00345.34% UpsideCurrent Analyst Ratings BreakdownLatest NDRA, COCH, NXGL, and XAIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025XAIRBeyond AirWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)10/8/2025COCHEnvoy MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NDRAENDRA Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NXGLNexGelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025COCHEnvoy MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NDRAENDRA Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NXGLNexGelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025XAIRBeyond AirWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/21/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/13/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.007/17/2025XAIRBeyond AirD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCHEnvoy Medical$220K91.99N/AN/A($0.88) per share-0.97NDRAENDRA Life SciencesN/AN/AN/AN/A$4.77 per shareN/ANXGLNexGel$8.69M2.19N/AN/A$0.90 per share2.62XAIRBeyond Air$3.70M5.29N/AN/A$3.32 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCHEnvoy Medical-$20.80M-$1.43N/AN/AN/A-10,961.26%N/A-236.14%11/13/2025 (Estimated)NDRAENDRA Life Sciences-$11.51M-$33.89N/AN/AN/AN/A-194.14%-127.89%11/21/2025 (Estimated)NXGLNexGel-$3.28M-$0.40N/A∞N/A-25.02%-49.37%-25.68%11/12/2025 (Estimated)XAIRBeyond Air-$46.62M-$11.93N/AN/AN/A-880.72%-232.61%-115.92%11/10/2025 (Estimated)Latest NDRA, COCH, NXGL, and XAIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025N/ACOCHEnvoy Medical-$0.31N/AN/AN/AN/AN/A11/12/2025Q3 2025NXGLNexGel-$0.08N/AN/AN/A$3.16 millionN/A11/10/2025Q2 2026XAIRBeyond Air-$1.10N/AN/AN/AN/AN/A8/14/2025Q2 2025NDRAENDRA Life Sciences-$2.27-$1.71+$0.56-$1.71N/AN/A8/12/2025Q2 2025NXGLNexGel-$0.07-$0.09-$0.02-$0.09$3.08 million$2.88 million8/12/2025Q1 2026XAIRBeyond Air-$1.50-$1.53-$0.03-$1.53$1.75 million$1.76 million7/31/2025Q2 2025COCHEnvoy Medical-$0.29-$0.32-$0.03-$0.32$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCHEnvoy MedicalN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ANXGLNexGelN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCHEnvoy MedicalN/A0.940.74NDRAENDRA Life SciencesN/A3.213.21NXGLNexGel0.161.740.98XAIRBeyond Air0.923.242.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCHEnvoy Medical8.59%NDRAENDRA Life Sciences1.19%NXGLNexGel2.21%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipCOCHEnvoy Medical58.90%NDRAENDRA Life Sciences0.04%NXGLNexGel20.55%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCHEnvoy Medical3423.81 million9.79 millionNot OptionableNDRAENDRA Life Sciences20750,000753,000Not OptionableNXGLNexGel108.07 million6.41 millionNot OptionableXAIRBeyond Air707.93 million6.40 millionOptionableNDRA, COCH, NXGL, and XAIR HeadlinesRecent News About These CompaniesWeiss Ratings Reiterates Sell (E) Rating for Beyond Air (NASDAQ:XAIR)October 16 at 2:39 AM | americanbankingnews.comFinancial Comparison: Inventiva (NASDAQ:IVA) vs. Beyond Air (NASDAQ:XAIR)October 13, 2025 | americanbankingnews.comBeyond Air files to sell 719,561 shares of common stock for holdersSeptember 25, 2025 | msn.comBeyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities ConferenceSeptember 22, 2025 | globenewswire.comBeyond Air Announces New Warrant AgreementSeptember 11, 2025 | msn.comBeyond Air, Inc. Announces Exercise of Warrants to Raise $3.25 Million for Clinical Programs and OperationsSeptember 8, 2025 | quiverquant.comQBeyond Air Announces Exercise of Warrants for $3.25 Million of Gross ProceedsSeptember 8, 2025 | globenewswire.comNeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in AdultsSeptember 8, 2025 | markets.businessinsider.comBeyond Air subsidiary granted orphan designation for malignant glioma treatmentSeptember 3, 2025 | msn.comBeyond Air, Inc. CEO Steve Lisi to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comBeyond Air, Inc. Expands Global LungFit® PH Distribution Network to 34 CountriesAugust 20, 2025 | quiverquant.comQBeyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanAugust 20, 2025 | globenewswire.comBeyond Air price target lowered to $5 from $20 at Piper SandlerAugust 14, 2025 | msn.comBeyond Air’s Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Call TranscriptAugust 13, 2025 | msn.comBeyond Air Reports Strong Revenue Growth in Q1 2026August 13, 2025 | msn.comBeyond Air reports Q1 EPS ($1.53) vs. ($5.32) last yearAugust 12, 2025 | msn.comBeyond Air, Inc. (XAIR) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comBeyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue EstimatesAugust 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNDRA, COCH, NXGL, and XAIR Company DescriptionsEnvoy Medical NASDAQ:COCH$0.85 -0.06 (-6.59%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$0.82 -0.03 (-2.94%) As of 10/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.ENDRA Life Sciences NASDAQ:NDRA$7.00 -0.41 (-5.53%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$6.39 -0.61 (-8.77%) As of 10/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.NexGel NASDAQ:NXGL$2.36 -0.17 (-6.72%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$2.37 +0.01 (+0.21%) As of 10/16/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Beyond Air NASDAQ:XAIR$2.47 -0.11 (-4.26%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$2.51 +0.04 (+1.62%) As of 10/16/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
